EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

14‐3‐3σ/Stratifin and p21 limit AKT‐related malignant progression in skin carcinogenesis following MDM2‐associated p53 loss

Carol M McMenemy, Dajiang Guo, Jean A Quinn, David A Greenhalgh iD

Molecular Carcinogenesis · 2024

DOI: 10.1002/mc.23771 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2024. Written by Carol M McMenemy and 3 co-authors. Institution: Section of Dermatology and Molecular Carcinogenesis, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, Gla…. Major MEDLINE topics: 14-3-3 Proteins, Skin Neoplasms, Proto-Oncogene Proteins c-mdm2, Tumor Suppressor Protein p53. Cited 1 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY 4.0). Funded by: Scott Endowment Fund for Dermatology, GU M.Res Research Program in Cancer Sciences, SFC/MRC M.Res in Integrative Mammalian Biology, Glasgow University.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

To study mechanisms driving/inhibiting skin carcinogenesis, stage‐specific expression of 14‐3‐3σ (Stratifin) was analyzed in skin carcinogenesis driven by activated ras Ha /fos expression ( HK1.ras/fos ) and ablation of PTEN ‐mediated AKT regulation ( K14.creP/Δ5PTEN flx/flx ). Consistent with 14‐3‐3σ roles in epidermal differentiation, HK1.ras hyperplasia and papillomas displayed elevated 14‐3‐3σ expression in supra‐basal keratinocytes, paralleled by supra‐basal p‐MDM2 166 activation and sporadic p‐AKT 473 expression. In bi‐genic HK1.fos/Δ5PTEN flx/flx hyperplasia, basal‐layer 14‐3‐3σ expression appeared, and alongside p53/p21, was associated with keratinocyte differentiation and keratoacanthoma etiology. Tri‐genic HK1.ras/fos‐Δ5PTEN flx/flx hyperplasia/papillomas initially displayed increased basal‐layer 14‐3‐3σ, suggesting attempts to maintain supra‐basal p‐MDM2 166 and protect basal‐layer p53. However, HK1.ras/fos‐Δ5PTEN flx/flx papillomas exhibited increasing basal‐layer p‐MDM2 166 activation that reduced p53, which coincided with malignant conversion. Despite p53 loss, 14‐3‐3σ expression persisted in well‐differentiated squamous cell carcinomas (wdSCCs) and alongside elevated p21, limited malignant progression via inhibiting p‐AKT1 473 expression; until 14‐3‐3σ/p21 loss facilitated progression to aggressive SCC exhibiting uniform p‐AKT1 473 . Analysis of TPA‐promoted HK1.ras‐Δ5PTEN flx/flx mouse skin, demonstrated early loss of 14‐3‐3σ/p53/p21 in hyperplasia and papillomas, with increased p‐MDM2 166 /p‐AKT1 473 that resulted in rapid malignant conversion and progression to poorly differentiated SCC. In 2D/3D cultures, membranous 14‐3‐3σ expression observed in normal HaCaT and SP1 ras61 papilloma keratinocytes was unexpectedly detected in malignant T52 ras61/v‐fos SCC cells cultured in monolayers, but not invasive 3D‐cells. Collectively, these data suggest 14‐3‐3σ/Stratifin exerts suppressive roles in papillomatogenesis via MDM2/p53‐dependent mechanisms; while persistent p53‐independent expression in early wdSCC may involve p21‐mediated AKT1 inhibition to limit malignant progression.

Subjects

MeSH terms (MEDLINE)

14-3-3 ProteinsSkin NeoplasmsProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Proto-Oncogene Proteins c-aktAnimalsMiceExoribonucleasesCarcinogenesisDisease ProgressionHumansCyclin-Dependent Kinase Inhibitor p21KeratinocytesGene Expression Regulation, Neoplastic

Author keywords

PTENTPA promotionfoskeratoacanthomaorganotypic culturerasskin carcinogenesistransgenic mouse

Substances

14-3-3 ProteinsProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53Proto-Oncogene Proteins c-aktExoribonucleasesSfn protein, mouseCyclin-Dependent Kinase Inhibitor p21Mdm2 protein, mouseTrp53 protein, mouse

Authors and institutions

  • Section of Dermatology and Molecular Carcinogenesis, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, Glasgow University, Glasgow, Scotland.
  • Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland.

ORCID profiles: David A Greenhalgh

Funding

  • Scott Endowment Fund for Dermatology
  • GU M.Res Research Program in Cancer Sciences
  • SFC/MRC M.Res in Integrative Mammalian Biology, Glasgow University
  • Wellcome Biomedical vacation scholarship

Cite

APA

McMenemy, C. M., Guo, D., Quinn, J. A., & Greenhalgh, D. A. (2024). 14‐3‐3σ/Stratifin and p21 limit AKT‐related malignant progression in skin carcinogenesis following MDM2‐associated p53 loss. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23771

Vancouver

McMenemy CM, Guo D, Quinn JA, Greenhalgh DA. 14‐3‐3σ/Stratifin and p21 limit AKT‐related malignant progression in skin carcinogenesis following MDM2‐associated p53 loss. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23771

BibTeX
@article{McMenemy2024,
  author = {McMenemy, Carol M and Guo, Dajiang and Quinn, Jean A and Greenhalgh, David A},
  title = {14‐3‐3σ/Stratifin and p21 limit AKT‐related malignant progression in skin carcinogenesis following MDM2‐associated p53 loss},
  journal = {Molecular Carcinogenesis},
  year = {2024},
  doi = {10.1002/mc.23771}
}
Start for free →